NCT03660878 - A Methodology Development Environmental Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 8, 2018

Primary Completion Date

November 19, 2019

Study Completion Date

November 19, 2019

Conditions

Allergic Conjunctivitis

Interventions

DRUG

Reproxalap Ophthalmic Solution (0.25%)

Reproxalap Ophthalmic Solution (0.25%) administered four times a day and an additional four times a day on an as needed basis.

DRUG

Reproxalap Ophthalmic Solution (0.5%)

Reproxalap Ophthalmic Solution (0.5%) administered four times a day and an additional four times a day on an as needed basis.

DRUG

Vehicle Ophthalmic Solution

Vehicle Ophthalmic Solution administered four times a day and an additional four times a day on an as needed basis.

Trial Locations (1)

Slade & Baker Vision, Houston